BioCryst rises on US FDA approval for oral formulation of rare disease drug

BioCryst Pharmaceuticals

12/12/2025 12:32

** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 2% to $7.73 premarket

** US FDA approves co's oral pellet formulation of once-daily drug Orladeyo for pediatric patients with hereditary angioedema

** Hereditary angioedema is a genetic disorder that causes episodes of swelling in different parts of a child's body, including in the face and hands

     ** Orladeyo is a prophylactic therapy designed to prevent attacks of hereditary angioedema

** Up to last close, stock up 0.8% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))